Ready-Made immune cells take on Hard-to-Treat cancers

NCT ID NCT07216105

First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 27 times

Summary

This early-stage study tests a new cancer treatment called FT836, which uses donor immune cells specially designed to attack tumors. It is for people with advanced lung, colorectal, breast, ovarian, endometrial, or head and neck cancers that have not responded to standard treatments. The study aims to find the safest dose and check if combining FT836 with chemotherapy or other antibodies is tolerable and effective.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • M. D. Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

    Contact

  • Thomas Jefferson University, Sidney Kimmel Cancer Center

    RECRUITING

    Philadelphia, Pennsylvania, 19107, United States

    Contact

  • UC San Diego Moores Cancer Center

    RECRUITING

    La Jolla, California, 92093, United States

  • University of Minnesota Masonic Cancer Center

    RECRUITING

    Minneapolis, Minnesota, 55455, United States

    Contact

  • University of Southern California

    RECRUITING

    La Jolla, California, 90033, United States

Conditions

Explore the condition pages connected to this study.